-

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Samantha Avivi appointed as new Chief Marketing Officer of Consumer Health, North America division. Current CMO Jeff Jarrett to retire after five years with Bayer.

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May.

“I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi. “She has expertise in setting groundbreaking visions, igniting breakthrough growth, accelerating multifunctional teams, with a proven track record of growing businesses, brands and most importantly, people.”

“I also want to sincerely thank Jeff Jarrett for his dedication to the company, to our mission, and to our people,” continued Tomasi. “He’s been a driver of innovation, a champion of marketing excellence, a key leader in advancing the turnaround of our Consumer Health business, and a huge advocate for Diversity, Equity & Inclusion at Bayer. While he is leaving Bayer, the friendships he’s forged here will continue, and I wish him all the best in this exciting next chapter.”

Samantha has over 25 years of client, retail and agency experience at some of the world’s largest companies like P&G, Kimberly Clark, Walmart, BBDO and Y&R. She was most recently the Chief Marketing Officer at Advance Auto Parts where she owned and executed the company’s omnichannel strategy and operations including a comprehensive marketing vision, philosophy, and plan. During her tenure, she inspired forward-looking programs in support of Advance Auto Parts and its portfolio of brands.

“I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol.”

Prior to Advance Auto Parts, Samantha was the CMO at Tenneco, where she led a portfolio of 31 brands across 42 product lines in 26 countries. Samantha is a graduate of the University of Florida with a Bachelor of Business Administration (BBA).

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to bayer.com.

Contacts

Christin Miller, Director of Strategic Communications, christin.miller@bayer.com

Bayer


Release Versions

Contacts

Christin Miller, Director of Strategic Communications, christin.miller@bayer.com

More News From Bayer

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o...

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen...

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...
Back to Newsroom